A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Japanese Pediatric Subjects With Short Bowel Syndrome Who Completed SHP633-302
Phase of Trial: Phase III
Latest Information Update: 15 Oct 2018
At a glance
- Drugs Teduglutide (Primary)
- Indications Short bowel syndrome
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shire
- 04 Oct 2018 Planned number of patients changed from 5 to 7.
- 18 May 2018 Planned End Date changed from 30 Apr 2020 to 1 Jun 2020.
- 18 May 2018 Planned primary completion date changed from 30 Apr 2020 to 1 Jun 2020.